Nov 5, 4:10 PM ET
Sarepta reported third quarter 2026 total revenues of $381.4 million, down $18.0 million (5%) from a year earlier, while GAAP operating loss narrowed to $9.0 million from $103.4 million. The company raised the low end of its full-year 2026 total net product revenue guidance by $50.0 million to $1.25 billion to $1.3 billion and lowered the high end of its expense guidance by $25.0 million to $800 million to $825 million.
- Q3 2026 total revenues were $381.4 million, versus $399.4 million in Q3 2025, a decrease of $18.0 million.
- Q3 2026 GAAP net loss was $28.5 million, or $(0.27) per diluted share, versus a $50.6 million loss a year earlier; non-GAAP net income was $15.6 million.
- 2026 total net product revenue guidance low end raised $50.0 million to $1.25 billion–$1.3 billion; combined non-GAAP R&D and SG&A expense guidance now $800 million–$825 million.
- Cash, cash equivalents, restricted cash and investments were $998.7 million as of September 30, 2026.
Read the filing on SEC.gov ↗
Sep 23, 4:13 PM ET
Sarepta Therapeutics entered a settlement agreement with REGENXBIO, the Trustees of the University of Pennsylvania and Catalent to resolve pending patent infringement litigation and an related appeal over several patents. Sarepta will pay REGENXBIO a lump sum of $39.0 million, an amount it had already recorded as a litigation contingency charge in the second quarter of 2026. The settlement releases Sarepta from past infringement claims and includes covenants not to sue for ELEVIDYS and other AAVrh74-based products, which removes a source of legal uncertainty for shareholders.
- Sarepta will pay REGENXBIO a $39.0 million lump sum within ten days of the September 23, 2026 Effective Date.
- The $39.0 million matches a litigation contingency charge recorded in the three and six months ended June 30, 2026.
- REGENXBIO and UPenn released claims up to the Effective Date and agreed not to sue over ELEVIDYS and other AAVrh74-based products under the UPenn Patents.
- The Litigations will be dismissed with prejudice, and the settlement includes no admission of liability.
Read the filing on SEC.gov ↗
Aug 5, 4:06 PM ET
Sarepta reported second quarter 2026 total revenues of $401.3 million, down 34% from $611.1 million a year earlier, and a GAAP net loss of $4.9 million, compared with GAAP net income of $196.9 million in the prior-year quarter. The company narrowed its 2026 total net product revenue guidance to $1.2 billion to $1.3 billion, lowering the top of its prior $1.2 billion to $1.4 billion range, and new CEO Michael Severino took office July 28, 2026.
- Q2 2026 total revenues were $401.3 million versus $611.1 million in Q2 2025; GAAP operating income was $13.3 million and non-GAAP operating income was $86.5 million.
- GAAP diluted loss per share was $(0.05) for the quarter, compared with GAAP diluted earnings per share of $1.89 a year earlier.
- FY 2026 total net product revenue guidance narrowed to $1.2 billion to $1.3 billion from $1.2 billion to $1.4 billion.
- A $39.0 million litigation contingency charge was recorded related to potential resolution of certain patent litigations; cash and investments were $945.0 million as of June 30, 2026.
Read the filing on SEC.gov ↗
Jul 27, 9:08 AM ET
Sarepta Therapeutics appointed Michael Severino, M.D., former CEO of Tessera Therapeutics, as chief executive officer effective July 28, 2026, and as a Class I director. Doug Ingram, the current CEO, departs as CEO and board member on that date and will serve as a consultant until December 31, 2026. The filing describes a sign-on equity package with a grant date value of approximately $35 million and a base salary of $1,180,000, which shareholders may track for compensation and leadership continuity.
- Michael Severino, M.D., becomes CEO and a director effective July 28, 2026, succeeding Doug Ingram
- Sign-on equity grant has an approximate grant date value of $35,000,000, including a $14,000,000 make-whole grant
- Severino's employment agreement sets an annual base salary of $1,180,000 and a target bonus of 110% of base salary
- Ingram will consult for the company until December 31, 2026, for a monthly fee of $15,000
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.